|
||||||
Recent Issues2010Spring Summer 2009 April June August October/November Winter 2009–2010 2008 May/June July/August September/October November/December 2007 February April June August October December 2006 February April June August October December 2005 February April June August October December 2004 March May July/August September October December About Biotechnology Healthcare JournalRate CardProduction Specifications Call for Papers Conflict-of-interest form (PDF) Writers’ Guidelines Masthead Editorial Board Subscriptions Reprints |
December 2005FeaturesCover Story Gene-Based Diagnostics: Ready for Prime Time?With so many tests in development, health care is preparing for a rush of changes with far-reaching effects. Diseases will be detected earlier and responses to drugs and treatment will be more predictable. Evidence of their effectiveness will dictate their acceptance. Devices Nanotechnology: What's in It for Biotech?Speculation is high about a technology that promises reduced medical costs and better outcomes through more efficient drug discovery, disease detection, and drug delivery. Medicare 8 Lessons Health Plans Learned From Participating in Part DHealth plans and manufacturers are scrambling toward the last great untapped market: Medicare. Getting there has been, well, half the fun. Business The Stealth Emergence of Contract Research OrganizationsQuickly and quietly, CROs have come to dominate the drug-testing arena. Clinical-trial recruitment and enrollment will never be the same. Economics Getting Discovery to the Commercial Arena: Not for the Faint of HeartMoving a new idea to market is a tenuous process that demands balance between investors and inventors and careful management of financial risk. Leading Edge Does Race Have a Place In Biotechnological Research?Controversy is exploding, and implications are surfacing with the FDA’s approval of a drug that presumes genetic differences between whites and blacks DepartmentsOpeners So Many Topics... So Little SpaceSome year-end food for thought. Editorial Public Health GenomicsDavid B. Nash, MD, MBA, demurs on genomics and population health. Washington Watch Pharmacovigilance: The New Drug-Development StandardPharmacovigilance equals a higher premium on risk management. DrugTrack Approvals, FDA Actions, Clinical Trials
Bob Carlson Diagnostics and Devices Task Force Breaks New Ground with Breast Cancer RecommendationsU.S. weighs evidence for genetic testing and counseling for breast cancer risk. Biotech Business Specialty Drug Costs Continue To Rise; Employees Hit With Higher PremiumsCost sharing on the rise as consumers pay a higher percentage of drug costs. Pipeline High-deductible Health Plans Must Account For Increased Specialty Drug UseBenefit design evolves for specialty drugs. |
|||||